Uniphar

FY 2019: delivering to plan; valuation highly attractive

  • Sectors : Pharma and healthcare
  • Companies : Uniphar

Ratings and price correct at time of issue.

  • Uniphar

    Closing Price: 130c

  • RATING 27/08/19

  • PREVIOUS RATING N/A

DAVY VIEW

Uniphar continues to build a track record post IPO of delivering on both strategy and numbers. This morning’s trading update suggests that it is on track to meet our 2019 forecasts. We have also put through 3-4% upgrades to 2020 and 2021 EPS forecasts to reflect recent MedTech M&A (EPS Group and M3 Medical). On 7.5x EV/EBITDA and 10.0x P/E, the company’s valuation doesn’t reflect the pan-European growth platform that it is building in Commercial & Clinical (C&C) and the global growth platform it has established in Product Access.

Download full report with analyst certification and important disclosures

Feb 4 2020, 07:15 GMT

Download